Cart
sales@molnova.com
1,5-Isoquinolinediol
CAS No. 5154-02-9
1,5-Isoquinolinediol ( —— )
Catalog No. M17727 CAS No. 5154-02-9
1, 5-Isoquinolinediol is an inhibitor of poly(ADP-ribose) synthetase (PARP1; IC50: 0.39 μM).
Purity : 98%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 52 | In Stock |
|
| 10MG | 78 | In Stock |
|
| 50MG | 172 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name1,5-Isoquinolinediol
-
NoteResearch use only, not for human use.
-
Brief Description1, 5-Isoquinolinediol is an inhibitor of poly(ADP-ribose) synthetase (PARP1; IC50: 0.39 μM).
-
Description1, 5-Isoquinolinediol is an inhibitor of poly(ADP-ribose) synthetase (PARP1; IC50: 0.39 μM). The poly(ADP-ribose) polymerases (PARPs) form a family of enzymes with roles in DNA repair and apoptosis. 1, 5-Isoquinolinediol has been used to study the role of PARP1 in both DNA repair and oxidant stress-induced cell death. This compound can be used with cells in culture and in animals.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPARP1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number5154-02-9
-
Formula Weight161.16
-
Molecular FormulaC9H7NO2
-
Purity98%
-
Solubility——
-
SMILESOc1cccc2c1cc[nH]c2=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Davar D, et al. Role of PARP inhibitors in cancer biology and therapy.[J]. Current Medicinal Chemistry, 2012, 19(23).
molnova catalog
related products
-
Canthin-6-one
Canthin-6-one (NSC 103003)is an alkaloid isolated from Allium neapolitanum with antibacterial activity and inhibitory effect against Mycobacterium tuberculosis.
-
Fmoc-Gly-Gly-OH
Fmoc-Gly-Gly-OH is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
-
Isosilybin
Isosilybin and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients.
